Hornick P, Harris P A, Taylor K M
Department of Cardiac Surgery, Royal Postgraduate Medical School, London, United Kingdom.
J Heart Valve Dis. 1996 Jan;5(1):20-5.
Earlier surgical intervention to the mitral and/or aortic valve means that it will be uncommon to replace the tricuspid valve (TVR) in a patient who has not had prior open heart surgery.
We report the short and medium term results of a consecutive series of 14 patients who underwent bioprosthetic TVR between December 1985 and February 1993 at the Hammersmith Hospital, UK. All patients had undergone previous open heart surgery on at least one occasion. Mean patient age was 59 years (range: 45-77 years), 11 were female and three were male. Ten patients (72%) were in New York Heart Association class III or IV preoperatively, eight patients were first time reoperations and six patients were second time reoperations.
Hospital mortality was 50% (7/14). Of these seven patients, six were in NYHA class III or IV preoperatively, and three were second time reoperations. There were no 'on-the-table deaths' and no patients required reoperation for bleeding or permanent pacing. For the patients discharged from hospital, the mean follow up was 46 months (range 9-84 months) and it was 100% complete. There was no significant difference in the preoperative assessment data between the hospital mortality group and the patients who left hospital (p > 0.05). Of the patients discharged, four (57% of this group, 28.5% of all patients) showed an improvement in NYHA classification and all patients reported a reduction in peripheral edema. Amongst the survivors there was 100% freedom from valve related complications. Within this group there have been three deaths since discharge, all due to biventricular failure.
From this study we conclude that TVR in patients who have had prior cardiac surgery is a high risk procedure. Nonetheless, amongst survivors, benefit may be gained by either a reduction in peripheral edema and/or an improvement in NYHA class.
对二尖瓣和/或主动脉瓣进行早期手术干预意味着,在未曾接受过心脏直视手术的患者中,进行三尖瓣置换术(TVR)的情况并不常见。
我们报告了1985年12月至1993年2月期间在英国哈默史密斯医院连续接受生物人工三尖瓣置换术的14例患者的短期和中期结果。所有患者此前至少接受过一次心脏直视手术。患者平均年龄为59岁(范围:45 - 77岁),11例为女性,3例为男性。10例患者(72%)术前为纽约心脏协会III级或IV级,8例患者为首次再次手术,6例患者为第二次再次手术。
医院死亡率为50%(7/14)。在这7例患者中,6例术前为纽约心脏协会III级或IV级,3例为第二次再次手术。术中无死亡病例,也没有患者因出血或永久性起搏需要再次手术。出院患者的平均随访时间为46个月(范围9 - 84个月),随访完整率为100%。医院死亡组和出院患者术前评估数据无显著差异(p > 0.05)。出院患者中,4例(该组的57%,所有患者的28.5%)纽约心脏协会分级有所改善,所有患者外周水肿均减轻。幸存者中瓣膜相关并发症发生率为0%。该组出院后有3例死亡,均因双心室衰竭。
从本研究我们得出结论,既往有心脏手术史的患者进行三尖瓣置换术是一项高风险手术。尽管如此,在幸存者中,外周水肿减轻和/或纽约心脏协会分级改善可能会带来益处。